KORTUC Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 8

KORTUC General Information

Description

Developer of radio sensitizing cancer treatment technology intended to improve the effectiveness of radiotherapy for solid tumors. The company's platform utilizes an injectable formulation based on hydrogen peroxide and sodium hyaluronate to reduce tumor hypoxia and address radiotherapy resistance, includes a prefilled injection device kit for clinical administration, supports integration with existing radiation treatment workflows, and is being evaluated across multiple solid tumor types, enabling healthcare providers to enhance radiotherapy outcomes for patients with treatment-resistant cancers.

Contact Information

Website
kortuc.com
Formerly Known As
Kortuc Usa
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 214 Homer Avenue
  • Palo Alto, CA 94301
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Vertical(s)
Corporate Office
  • 214 Homer Avenue
  • Palo Alto, CA 94301
  • United States

KORTUC Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KORTUC Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 01-Jul-2026 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series B) 08-Aug-2025 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series C) 05-Nov-2021 Completed Clinical Trials - Phase 2
4. Early Stage VC 20-Sep-2019 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 10-Jan-2019 Completed Clinical Trials - Phase 1
2. Early Stage VC 28-Dec-2017 $868K $1.75M Completed Clinical Trials - Phase 1
1. Seed Round 28-Feb-2017 $884K $884K Completed Clinical Trials - Phase 1
To view KORTUC’s complete valuation and funding history, request access »

KORTUC Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class C Preferred
Class B Preferred
Class A3 Preferred
Class A2 Preferred 1,633 $528.14 $528.14 $528.14 8.94%
Class A Preferred 2,380 $369.7 $369.7 $369.7 13.03%
To view KORTUC’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

KORTUC Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of radio sensitizing cancer treatment technology intended to improve the effectiveness of radiotherapy for sol
Biotechnology
Palo Alto, CA
3 As of 2026

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

KORTUC Competitors (1)

One of KORTUC’s competitors is Nanobiotix, a Formerly VC-backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nanobiotix Formerly VC-backed Paris, France
You’re viewing 1 of 1 competitors. Get the full list »

KORTUC Patents

KORTUC Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4166147-A1 Sensitiser for cancer treatment Inactive 15-Jun-2020
EP-4166147-A4 Sensitiser for cancer treatment Inactive 15-Jun-2020
WO-2021256427-A1 Sensitiser for cancer treatment Inactive 15-Jun-2020
JP-2022168328-A Sensitizer for anticancer therapy Pending 15-Jun-2020
JP-2021000262-A Syringe and kit suitable for hydrogen peroxide solution Active 21-Jun-2019
To view KORTUC’s complete patent history, request access »

KORTUC Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KORTUC Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Loyal VC Venture Capital Minority
Midas Capital (Japan) PE/Buyout Minority
AXA Japan Corporation Minority
Irimajiri Group Corporation Minority
SBI Investment Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

KORTUC FAQs

  • When was KORTUC founded?

    KORTUC was founded in 2015.

  • Where is KORTUC headquartered?

    KORTUC is headquartered in Palo Alto, CA.

  • What is the size of KORTUC?

    KORTUC has 3 total employees.

  • What industry is KORTUC in?

    KORTUC’s primary industry is Biotechnology.

  • Is KORTUC a private or public company?

    KORTUC is a Private company.

  • What is KORTUC’s current revenue?

    The current revenue for KORTUC is .

  • How much funding has KORTUC raised over time?

    KORTUC has raised $44.4M.

  • Who are KORTUC’s investors?

    Loyal VC, Midas Capital (Japan), AXA Japan, Irimajiri Group, and SBI Investment are 5 of 8 investors who have invested in KORTUC.

  • Who are KORTUC’s competitors?

    Nanobiotix is a competitor of KORTUC.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process